{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:06Z","timestamp":1790409246774,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR\u2010MAD\u20102022\u201012375673"],"award-info":[{"award-number":["PNRR\u2010MAD\u20102022\u201012375673"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta\u2010drug refractory patients continue to be the hard core of relapsed\/refractory (RR) settings. Teclistamab\u2010cqyv is a humanized IgG4 antibody and a bispecific BCMA\u2010director CD3 T\u2010cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab\u2010cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti\u2010CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives.<\/jats:p>","DOI":"10.1111\/ejh.14121","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:01:11Z","timestamp":1697587271000},"page":"320-327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Teclistamab\u2010cqyv in multiple myeloma"],"prefix":"10.1111","volume":"112","author":[{"given":"Enrica Antonia","family":"Martino","sequence":"first","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-2404","authenticated-orcid":false,"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Labanca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Neri","sequence":"additional","affiliation":[{"name":"Scientific Directorate IRCCS of Reggio Emilia  Reggio Emilia Emilia\u2010Romagna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-7073","authenticated-orcid":false,"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Biotechnology Research Unit AO of Cosenza  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera Annunziata  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria  Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S306103"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3035"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3031"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283251"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00797-8"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2218543"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2193289"},{"key":"e_1_2_13_17_1","first-page":"1","article-title":"Elotuzumab in multiple myeloma","volume":"14","author":"Bruzzese A","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241513"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1274973"},{"key":"e_1_2_13_20_1","first-page":"1","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"3","author":"Gentile M","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_13_22_1","unstructured":"Consulted on 27th June 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.2.7"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2299"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162709"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"issue":"1","key":"e_1_2_13_30_1","first-page":"394","article-title":"Teclistamab in combination with subcutaneous Daratumumab and Lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC\u20102, a Phase1b","volume":"140","author":"Searle E","year":"2022","journal-title":"Multicohort Study Blood"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159756"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160173"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8006"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00735-4"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157525"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02480-7"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20044"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8049"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158801"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:25:50Z","timestamp":1708050350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/ejh.14121"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14121","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"2023-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}